Molecular Innovations Toward Theranostics of Aggressive Prostate Cancer
Abstract
In this project, we proposed to develop a new drug delivery vehicle based on dendrimer nanotechnology for personalized medicine. This new class of nanoplatforms contains imaging probe and molecular medicine with a cancer-specific targeting capability which is able to target cancer cells, monitor drug delivery and tumor response to achieve a see and treat strategy as a new concept of molecular medicine. Specifically, One partner PIs lab will make dendrimers bearing functional handles to conjugate with chelating agents provided by the initiating PIs lab for PET imaging and therapeutic peptides provided by another partner PIs lab for the treatment of aggressive prostate cancer. Within the funding period, we have designed and synthesized the proposed bifunctional chelator scaffold system, CB-TE2A(tBu)2-N3 for the further construction of theranostic agents and multi-modality imaging probes for aggressive prostate cancer. In the meanwhile, we have designed a targeted theranostic small molecule drug conjugate (T-SMDC) system, and successfully synthesized a sample compound of T-SMDC, which consists of a PSMA-specific ligand, a PET imaging moiety, and a cytotoxic drug. The resulted T-SMDC retains the PSMA binding affinity and exhibits PSMA-dependent toxicity. Built upon the the ranostic platforms and experimental data obtained, two new projects have been proposed and submitted to funding agencies including this prostate cancer research program.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2017
- Accession Number
- AD1050550
Entities
People
- Xiankai Sun
Organizations
- University of Texas Southwestern Medical Center